A nurse is providing education of enoxaparin to a patient diagnosed with deep venous thrombosis. Which statement by the patient indicates understanding of the teaching?

A. Urinary retention: While urinary retention can occur in conditions such as benign prostatic hyperplasia or neurogenic bladder, it is not a typical manifestation of hypertensive emergency. Hypertensive emergencies primarily involve acute and severe elevations in blood pressure, which can lead to target organ damage, but urinary retention is not a direct consequence.

B. Headache: Headache is a common symptom associated with hypertension, especially during hypertensive emergencies. However, it is not specific to hypertensive emergencies and can occur in less severe cases of hypertension as well.

C. Jaundice: Jaundice is not a typical manifestation of hypertensive emergency. It is more commonly associated with liver dysfunction or hemolytic disorders rather than acute elevations in blood pressure.

D. Tachycardia: Tachycardia, or an elevated heart rate, is a hallmark sign of hypertensive emergency. When blood pressure rises significantly, the heart may respond by increasing its rate to maintain cardiac output. Tachycardia is indicative of the body's compensatory mechanisms in response to the acute hypertension and can be a sign of impending cardiovascular complications.

A. "It eliminates the clotting factors." - This statement suggests a misunderstanding of how enoxaparin works. Enoxaparin is a low molecular weight heparin that does not eliminate clotting factors but rather inhibits the activity of factor Xa, a key enzyme involved in the coagulation cascade. By inhibiting factor Xa, enoxaparin prevents the conversion of prothrombin to thrombin, thereby reducing the formation of fibrin clots. It does not eliminate existing clotting factors from the bloodstream.

B. "This medication will keep the blood clot from growing larger." - This statement demonstrates a correct understanding of enoxaparin's mechanism of action. Enoxaparin is an anticoagulant medication that works by preventing the enlargement of existing blood clots. By inhibiting the activity of factor Xa, enoxaparin prevents the conversion of prothrombin to thrombin, thereby reducing the formation of fibrin clots and preventing existing clots from growing larger.

C. "This medication will decrease my risk for bleeding." - This statement is incorrect. Enoxaparin, like other anticoagulants, actually increases the risk of bleeding due to its mechanism of action. By inhibiting the coagulation cascade, enoxaparin prolongs the time it takes for blood to clot, which can lead to an increased risk of bleeding, particularly in patients who are predisposed to bleeding or are taking other medications that affect clotting.

D. "I will get this medication in my veins." - This statement is incorrect. Enoxaparin is administered subcutaneously, not intravenously. It is usually injected into the fatty tissue of the abdomen or thigh using a prefilled syringe with a short, thin needle. The subcutaneous route of administration allows for slow absorption and sustained anticoagulant effects over time.